Tyrosine hydroxylase (TH) is the rate-limiting enzyme in the biosynthetic pathway for catecholamines, catalyzing the conversion of L-tyrosine to L-DOPA (L-3,4-dihydroxyphenylalanine). This enzyme plays a pivotal role in the biosynthesis of [dopamine](/entities/dopamine), [norepinephrine](/entities/norepinephrine), and [epinephrine](/entities/epinephrine). In the central nervous system (CNS), TH is predominantly expressed in catecholaminergic neurons of the substantia nigra pars compacta (SNpc), ventral tegmental area (VTA), locus coeruleus, and other brain regions. The enzyme's activity is essential for maintaining dopamine levels critical for motor control, reward processing, and cognitive function. Loss of TH activity is a hallmark of Parkinson's disease (PD), where degeneration of dopaminergic neurons in the SNpc leads to characteristic motor symptoms [@leviel2010].
Tyrosine hydroxylase (TH) is the rate-limiting enzyme in the biosynthetic pathway for catecholamines, catalyzing the conversion of L-tyrosine to L-DOPA (L-3,4-dihydroxyphenylalanine). This enzyme plays a pivotal role in the biosynthesis of [dopamine](/entities/dopamine), [norepinephrine](/entities/norepinephrine), and [epinephrine](/entities/epinephrine). In the central nervous system (CNS), TH is predominantly expressed in catecholaminergic neurons of the substantia nigra pars compacta (SNpc), ventral tegmental area (VTA), locus coeruleus, and other brain regions. The enzyme's activity is essential for maintaining dopamine levels critical for motor control, reward processing, and cognitive function. Loss of TH activity is a hallmark of Parkinson's disease (PD), where degeneration of dopaminergic neurons in the SNpc leads to characteristic motor symptoms [@leviel2010].
<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Tyrosine Hydroxylase</th></tr>
<tr><td><strong>Protein Name</strong></td><td>Tyrosine Hydroxylase</td></tr>
<tr><td><strong>Gene Symbol</strong></td><td>[TH](/genes/th)</td></tr>
<tr><td><strong>UniProt ID</strong></td><td>[P07101](https://www.uniprot.org/uniprot/P07101)</td></tr>
<tr><td><strong>PDB Structures</strong></td><td>6HC8, 6HC9, 4XFY, 5TO1</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>58.5 kDa (per subunit)</td></tr>
<tr><td><strong>Length</strong></td><td>528 amino acids</td></tr>
<tr><td><strong>Quaternary Structure</strong></td><td>Homotetramer</td></tr>
<tr><td><strong>Subcellular Localization</strong></td><td>Cytoplasm; associated with vesicles</td></tr>
<tr><td><strong>Protein Family</strong></td><td>Tyrosine hydroxylase family (aromatic amino acid hydroxylases)</td></tr>
<tr><td><strong>Expression</strong></td><td>High in SNpc, VTA, locus coeruleus</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/cancer" style="color:#ef9a9a">CANCER</a>, <a href="/wiki/depression" style="color:#ef9a9a">DEPRESSION</a>, <a href="/wiki/parkinson" style="color:#ef9a9a">PARKINSON</a>, <a href="/wiki/parkinson's-disease" style="color:#ef9a9a">Parkinson's Disease</a>, <a href="/wiki/tumor" style="color:#ef9a9a">TUMOR</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">183 edges</a></td>
</tr>
</table>
</div>
TH belongs to the aromatic amino acid hydroxylase family, which also includes phenylalanine hydroxylase (PAH) and tryptophan hydroxylase (TPH). The enzyme has a characteristic tetrameric quaternary structure, with each subunit capable of independent catalytic activity.
Each TH subunit comprises three major functional domains:
N-terminal Regulatory Domain (aa 1-160)
The N-terminal region contains the regulatory domain that controls enzyme activity in response to neuronal signaling. This domain contains multiple phosphorylation sites (Ser8, Ser19, Ser31, Ser40) that modulate TH activity through phosphorylation-dependent mechanisms. The regulatory domain also contains the binding site for the endogenous inhibitor dopamine, providing feedback regulation of TH activity.
Catalytic Domain (aa 161-400)
The central catalytic domain contains the active site where the hydroxylation of L-tyrosine occurs. This domain binds the pterin cofactor tetrahydrobiopterin (BH4) and the iron necessary for catalytic activity. The catalytic domain shares significant sequence homology with PAH and TPH, with conserved residues required for binding substrate, cofactor, and iron.
C-terminal Domain (aa 401-528)
The C-terminal domain contributes to tetramer formation and protein-protein interactions. This region contains sequences involved in homooligomerization and association with regulatory proteins.
The catalytic center of TH contains:
TH functions as a homotetramer, with subunits arranged in a dimer-of-dimers configuration. Oligomerization is mediated by C-terminal interactions and is essential for enzyme stability and proper regulation. Tetramer formation can be modulated by phosphorylation and protein-protein interactions.
TH catalyzes the rate-limiting step in dopamine biosynthesis:
L-Tyrosine →[TH/BH4/O₂]→ L-DOPA →[AADC]→ Dopamine →[DBH]→ Norepinephrine →[PNMT]→ Epinephrine
The reaction requires:
TH activity is dynamically regulated by phosphorylation at multiple serine residues:
Ser40 (Major Regulatory Site)
Phosphorylation at Ser40 by several kinases (PKA, CaMKII, ERK1/2, MAPKAPK2) dramatically increases TH activity (up to 10-fold). This phosphorylation reduces the Km for L-tyrosine and decreases inhibition by dopamine. Ser40 phosphorylation is the primary mechanism linking neuronal activity to catecholamine synthesis.
Ser19
Phosphorylation at Ser19, primarily by CaMKII, promotes subsequent phosphorylation at Ser40 and increases TH stability. This site also mediates binding of 14-3-3 proteins, which further stimulate TH activity.
Ser31
Phosphorylation at Ser31 by ERK1/2 provides moderate activation (approximately 2-fold increase) and may regulate TH localization within neurons.
Ser8
Phosphorylation at Ser8, by PKA or other kinases, contributes to overall activation but plays a lesser role than Ser40.
Dopamine and other catecholamines provide feedback inhibition of TH activity through:
TH activity is tightly coupled to neuronal firing rates. Increased neuronal activity leads to:
TH deficiency is a central feature of Parkinson's disease pathology:
Loss of TH in SNpc Neurons
In PD, the dopaminergic neurons of the substantia nigra pars compacta (SNpc) undergo progressive degeneration. These neurons are the primary source of TH in the brain, and their loss leads to severe reductions in striatal dopamine content. TH activity in remaining neurons is also reduced due to:
TH as Biomarker
TH expression in blood and CSF is being explored as a biomarker for:
Autosomal dominant mutations in the TH gene cause Segawa syndrome, also known as dopa-responsive dystonia (DRD). This disorder is characterized by:
Rare autosomal recessive TH deficiency causes a more severe phenotype than Segawa syndrome:
While primarily a dopaminergic enzyme, TH is affected in AD through:
Locus Coeruleus Degeneration
The locus coeruleus (LC), the main source of norepinephrine in the brain, degenerates in AD. TH-expressing neurons in the LC are lost, leading to:
In MSA, TH deficiency in striatal and cortical regions contributes to:
L-DOPA (levodopa), combined with carbidopa or benserazide (peripheral DOPA decarboxylase inhibitors), remains the gold standard treatment for TH-related disorders:
Mechanism: L-DOPA bypasses the rate-limiting TH step, directly providing substrate for AADC to synthesize dopamine.
Pharmacokinetics:
Viral vector-mediated TH gene delivery is being developed as a potential treatment:
AAV-Mediated TH Delivery
Recombinant adeno-associated viruses (AAV) carrying the TH gene can be delivered to the striatum, where they transduce neurons to produce TH locally. This approach aims to:
BH4 Supplementation
Tetrahydrobiopterin (BH4) is the essential cofactor for TH. Supplementing BH4 may enhance residual TH activity in patients with cofactor deficiency. However, BH4 does not cross the blood-brain barrier efficiently, limiting its utility.
Modulators of TH Phosphorylation
Developing compounds that enhance TH phosphorylation at activating sites (Ser40) could boost residual enzyme activity.
Enhancing TH Expression
Transcription factors that increase TH gene expression (e.g., Nurr1, Pitx3) are being explored as neuroprotective strategies.
Stabilizing TH Protein
Preventing TH degradation through autophagy or the ubiquitin-proteasome system could preserve residual enzyme activity.